S. Korea Weighs Lab Return Of Disgraced Cloning Scientist (S. Korea)
This article was originally published in PharmAsia News
Executive Summary
South Korea's Ministry of Health is weighing a request by a disgraced cloning scientist to be allowed to conduct embryonic stem cell research once again, this time not as a team leader. Hwang Woo-suk and his base laboratory, Suam Bioengineering Research Institute, applied to the ministry's director in charge of bioethics safety for permission to do the research. The same type of work led to Hwang's downfall after it was discovered he and his team faked laboratory results, an issue still alive in the courts. The institute plans to return to Hwang's project of using somatic cells from specific patients to grow stem cells tailored to that patient. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.